BACKGROUND AND AIMS: @entity40204 has been reported to have antiproteinuric and nephroprotective properties. We investigated the effects of long-term low-dose @entity40204 on @entity644 and renal function in @entity1 with @entity740 ( @entity740 ) caused by @entity2316 ( @entity2316 ), @entity101 ( @entity101 ) and primary @entity631 ( @entity631 ). MATERIAL AND METHODS: 100 @entity1 with @entity740 received low-dose @entity40204 50 mg/day for 12 months. Treatment efficacy was evaluated as @entity644 reduction compared to baseline; response was defined as a decline in @entity644 below 0.3 g/d. Renal function evolution was assessed by @entity470 variation from baseline. RESULTS: All @entity1 presented @entity644 , with global mean value of @entity644 decrease of 0.85 +/- 1.34 g/d (p<0.0001). @entity1 with @entity101 had the highest mean percentage of @entity644 reduction (73 +/- 29%) and the lowest mean time period to achieve responder status (6.6 +/- 2.4 months), compared to @entity1 with @entity2316 (57 +/- 29%, 8 +/- 2.9 months) and @entity631 (63 +/- 24%, 10.7 +/- 1.2 months). Renal function as mean @entity470 remained stable or improved during the study; significant increase was found only in @entity101 group (3.41 +/- 6.38 ml/min/1.73 m2, p=0.043). Multivariate regression analysis identified that responder status was significantly associated with gender, baseline @entity470 , baseline @entity644 and etiology of @entity740 . Concomitant administration of ACEIs or/and ARBs did not influence the response to @entity40204 therapy. CONCLUSIONS: Independently of ACEIs or/and ARBs therapy, long-term low-dose @entity40204 is efficient as antiproteinuric and renoprotective therapy in @entity1 with @entity740 caused by @entity2316 , @entity631 and @entity101 . Better response is achieved in @entity1 with @entity8 .

Efficacy of long-term low-dose XXXX in diabetic and non-diabetic @entity8 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity644 :: ('MESH:D011507', 'Disease') :: ['reduction of proteinuria', 'proteinuria'] @entity8 :: ('MESH:D007674', 'Disease') :: ['lower degree of renal dysfunction'] @entity101 :: ('MESH:D006973', 'Disease') :: ['HN', 'hypertensive nephropathy'] @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic nephropathy', 'DN'] @entity470 :: ('1956', 'Gene') :: ['eGFR'] @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease'] @entity40204 :: ('MESH:C007858', 'Chemical') :: ['Sulodexide'] @entity631 :: ('MESH:D005921', 'Disease') :: ['GN', 'glomerulonephritis']
@entity40204 :: (MESH:C007858,Chemical) :: ['sulodexide']
